Database→CagriSema

Tier 1-2Weight LossMetabolicDiabetesPREMIUM

CagriSema

CagriSema (Cagrilintide 2.4 mg / Semaglutide 2.4 mg)

Not FDA-approved. NDA filed December 18, 2025 for chronic weight management. FDA decision anticipated late 2026. Not approved in EU or elsewhere. Cannot be compounded under federal law.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

CagriSema is a fixed-dose combination of cagrilintide 2.4 mg (long-acting amylin analogue) and semaglutide 2.4 mg (GLP-1 receptor agonist), once weekly subcutaneous. REDEFINE 1 (n=3,417, 68 weeks): 20.4% weight loss (ITT) vs 3.0% placebo, exceeding semaglutide alone (14.9%) by 5.5 points. REDEFINE 2 (n=1,206, T2D): 15.7% weight loss. REDEFINE 4 head-to-head vs tirzepatide 15 mg (n=809, 84 weeks, open-label): CagriSema 23% vs tirzepatide 25.5%, noninferiority not met. NDA filed December 2025, decision expected late 2026. If approved, would be the first GLP-1/amylin combination product.

🔒

Full Profile: Premium Members Only

The complete CagriSema profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use